// App-Quantinova.ai

TPS5094 : A phase II trial of cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219).

Researchers

Presenter

  • Petros Grivas

Principal Investigators

  • Stephanie Daignault

  • Kathleen A. Cooney

  • Rohit Mehra

  • June Escara-Wilke

  • Greg Shelley

  • Kenneth James Pienta

  • Maha Hussain

  • David C. Smith

  • Jon Jacobson

  • Corrie Yablon

  • Brian Dale Ross

  • Thomas L Chenevert

  • Craig J Galban

  • Alnawaz Rehemtulla

  • Evan T. Keller

  • Priya Kunju

Medical Centers

  • University of Michigan, Ann Arbor, MI

  • University of Michigan Medical School, Ann Arbor, MI

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Bone metastases

  • Solid malignancies

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Cabozantinib

  • Doxycycline

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01428219

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved